MXPA04003717A - Tableta masticlabe que contiene lisina. - Google Patents

Tableta masticlabe que contiene lisina.

Info

Publication number
MXPA04003717A
MXPA04003717A MXPA04003717A MXPA04003717A MXPA04003717A MX PA04003717 A MXPA04003717 A MX PA04003717A MX PA04003717 A MXPA04003717 A MX PA04003717A MX PA04003717 A MXPA04003717 A MX PA04003717A MX PA04003717 A MXPA04003717 A MX PA04003717A
Authority
MX
Mexico
Prior art keywords
chewable tablet
tablet containing
lysine
containing lysine
optionally
Prior art date
Application number
MXPA04003717A
Other languages
English (en)
Inventor
David Marocchi Michael
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MXPA04003717A publication Critical patent/MXPA04003717A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere a una tableta masticable con adaptabilidad mejorada para humanos, en particular ninos y/o adolescentes, que comprende al menos un vitamina, opcionalmente un mineral, lisina o una sal del mismo farmaceuticamente aceptable, al menos un endulcolorante que tiene la capacidad de enmascarar el sabor desagradable de la lisina, opcionalmente un agente saborizante y un portador farmaceuticamente o dieteticamente aceptable.
MXPA04003717A 2001-10-23 2002-10-23 Tableta masticlabe que contiene lisina. MXPA04003717A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10152169 2001-10-23
PCT/EP2002/011843 WO2003035027A1 (en) 2001-10-23 2002-10-23 Chewable tablet containing lysine

Publications (1)

Publication Number Publication Date
MXPA04003717A true MXPA04003717A (es) 2004-07-30

Family

ID=7703361

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04003717A MXPA04003717A (es) 2001-10-23 2002-10-23 Tableta masticlabe que contiene lisina.

Country Status (16)

Country Link
EP (1) EP1439818B1 (es)
JP (1) JP2005506364A (es)
AR (1) AR036937A1 (es)
AT (1) ATE285753T1 (es)
BR (1) BR0213449A (es)
CA (1) CA2463259C (es)
DE (1) DE60202489T2 (es)
ES (1) ES2236589T3 (es)
HU (1) HUP0402528A2 (es)
MX (1) MXPA04003717A (es)
PL (1) PL368342A1 (es)
PT (1) PT1439818E (es)
RU (1) RU2324474C2 (es)
UA (1) UA78242C2 (es)
UY (1) UY27505A1 (es)
WO (1) WO2003035027A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1658079T3 (da) 2003-08-19 2012-07-23 Pharmaton Sa Multivitaminsirup til børn eller unge voksne
JP2005272401A (ja) * 2004-03-25 2005-10-06 Tendou Seiyaku Kk チュアブル錠
WO2005094842A1 (en) * 2004-03-30 2005-10-13 Transition Therapeutics Inc. Vitamin b12-containing compositions and methods of use
JP4954450B2 (ja) * 2004-06-14 2012-06-13 ビーエーエスエフ ビューティ ケア ソリューションズ フランス エスエーエス 弾性繊維形成の不全、欠損又は無秩序による病状に対処するための、リシルオキシダーゼのアイソフォームの活性の誘導
US8491937B2 (en) * 2007-02-15 2013-07-23 Wyeth Llc Stability in vitamin and mineral supplements
DE502008002299D1 (de) * 2007-02-23 2011-02-24 Brain Biotechnology Res & Information Network Ag Verfahren zur geschmacksmodulation von stofflichen zusammensetzungen, die mindestens einen high intensity sweetener (his) enthalten
EP2131811B1 (fr) * 2007-03-14 2020-03-04 Vetinnov Produit appétent
RU2391109C1 (ru) * 2008-12-09 2010-06-10 Открытое Акционерное Общество "Инвестиционная Финансовая Группа "Гленик-М" Средство лечения онкологических заболеваний с использованием изотопа кальций-41
DE202012103733U1 (de) * 2012-09-28 2012-11-15 Reiner Rittinghausen Zusammensetzung zur nutritiven Ergänzung oder Behandlung bei Herpes
US9801821B2 (en) * 2013-03-27 2017-10-31 Psm Healthcare Limited Stabilized vitamin D formulations
CN107105748A (zh) 2014-09-25 2017-08-29 纽奇瑞迪专业有限公司 在青春期前的少年中用于促生长的营养补充剂
CN104688774A (zh) * 2015-02-17 2015-06-10 胡梨芳 包含手性异构化合物的赖氨酸磷酸氢钙药物组合物及其用途
CN108337879B (zh) * 2015-07-12 2021-01-19 西夫索有限公司 硫酸胆钙化醇的盐及其用于治疗维生素d3缺乏的用途
EP3213747B1 (en) * 2016-03-04 2019-02-13 Laboratorio Reig Jofre S.A. Tablets with a high-content of active ingredients useful for treating hair loss or stimulating its growth
CN107854457A (zh) * 2016-09-22 2018-03-30 刘力 包括手性异构化合物的葡萄糖酸钙锌组合物及其用途
US11547688B2 (en) * 2019-08-22 2023-01-10 Nodari Rizun Amino acid compositions and methods of manufacturing the compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2887437A (en) * 1956-08-22 1959-05-19 Pfizer & Co C Palatable vitamin tablet containing an amino acid
FR2215950A2 (en) * 1973-02-01 1974-08-30 Union Pharma Scient Appl Carbonated lysine - as carbonate source in effervescent compositions
US3970750A (en) * 1974-10-08 1976-07-20 Sandoz, Inc. Effervescent potassium chloride composition
JPH06227974A (ja) * 1993-01-29 1994-08-16 Kyowa Hakko Kogyo Co Ltd 栄養組成物
US20020081360A1 (en) * 2000-12-27 2002-06-27 Andreas Burgard Salts of L-amino acid having improved taste and their preparation

Also Published As

Publication number Publication date
EP1439818B1 (en) 2004-12-29
CA2463259C (en) 2011-01-04
UA78242C2 (en) 2007-03-15
WO2003035027A1 (en) 2003-05-01
PT1439818E (pt) 2005-03-31
AR036937A1 (es) 2004-10-13
EP1439818A1 (en) 2004-07-28
UY27505A1 (es) 2003-06-30
PL368342A1 (en) 2005-03-21
HUP0402528A2 (hu) 2005-07-28
DE60202489D1 (de) 2005-02-03
ATE285753T1 (de) 2005-01-15
DE60202489T2 (de) 2006-01-05
JP2005506364A (ja) 2005-03-03
BR0213449A (pt) 2004-11-09
CA2463259A1 (en) 2003-05-01
RU2004115755A (ru) 2005-04-10
ES2236589T3 (es) 2005-07-16
RU2324474C2 (ru) 2008-05-20

Similar Documents

Publication Publication Date Title
MXPA04003717A (es) Tableta masticlabe que contiene lisina.
NO2017047I1 (no) Tofacitinib, evt. i form av et farmasøytisk akseptabelt salt, inkludert citratsalt
FR11C0017I1 (es)
ZA200606173B (en) Effervescent oral opiate dosage form
HK1061679A1 (en) Phenylsulfonyl-1,3-dihydro-2h-indole-2-ibe derivatives, their preparation and their therapeutic use.
AU2003280087A1 (en) Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton
HRP20041152B1 (en) Pharmaceutical formulations
TR199800602A3 (tr) Dithiolan türevleri, hazirlanmalari ve terapötik etkileri.
WO2000003742A3 (en) Solid oral dosage form comprising a combination of metformin and glibenclamide
WO2004056337A3 (en) Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
MXPA03007712A (es) Sales farmaceuticas.
HN1997000151A (es) Forma de dosificacion farmaceutica que enmascara el sabor y que se libera rapidamente.
WO2002047668A3 (de) Neue arzneimittelkompositionen auf der basis von anticholinergika und ciclesonide
AU2682401A (en) Flavonoid drug and dosage form, its production and use
IL151400A0 (en) Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use
ATE287264T1 (de) Oral anzuwendende buprenorphinhaltige arzneimittel
AU2001264042A1 (en) 1,4-diazabicyclo(3.2.2)nonane-phenylisoxazole derivatives, preparation and therapeutic use thereof
WO2002053149A3 (de) Arzneimittel enthaltend ein polyamin als wirksubstanz
TWI320413B (en) 1,4-diazabicyclo [ 3.2.2 ] nonanecarboxamide derivatives, preparation thereof and therapeutic use thereof
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
NO20040857L (no) Ny oral forlenget frigivelses doseringsform.
MXPA03006162A (es) Derivados de mikanolida, su preparacion y sus usos terapeuticos.
EP1571148A4 (en) APPROVED OF 3-PHENYLCINNOLINE AND ANTI-TUMOR AGENT CONTAINING THE SAME
IL161859A0 (en) 3-Heteroaryl-3.5-dihydro-4-oxo-4H-pyridazinoÄ4.5-BÜindole-1-carboxamide derivatives, their preparation and therapeutic use
WO2002009668A3 (en) Pulmonary administration of flint

Legal Events

Date Code Title Description
GB Transfer or rights
FG Grant or registration